Alumis Inc.
ALMS
Kedudukan dalam Saham
#10174
Alumis Inc., a clinical stage biopharmaceutical company, focuses on the... Alumis Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of medicines for autoimmune disorders. The company offers envudeucitinib, a tyrosine kinase 2 (TYK2) inhibitor for the treatment of plaque psoriasis and systemic lupus erythematosus; and A-005, a central nervous system-penetrant allosteric TYK2 inhibitor that is in Phase 1 for the treatment of neuroinflammatory and neurodegenerative diseases. It also develops lonigutamab, a monoclonal antibody targeting IGF-1R for the treatment of thyroid eye diseases; and interferon regulatory factor 5 (IRF5) to address immune dysfunction. The company was formerly known as Esker Therapeutics, Inc. and changed its name to Alumis Inc. in January 2022. Alumis Inc. was incorporated in 2021 and is headquartered in South San Francisco, California.
Harga Saham
$6.41
Disegerakkan terakhir: 2026-10-19
Modal Pasaran
$830.25M
Perubahan (1 hari)
4.81%
Perubahan (1 tahun)
182.57%
Negara
US
Perdagangan Alumis Inc. (ALMS)
Kategori
Healthcare
Bilangan saham terbitan bagi Alumis Inc. (ALMS)
Bilangan saham terbitan setakat March 2025: 100.68M
Menurut laporan kewangan terkini dan harga saham Alumis Inc., bilangan saham terbitan semasa ialah 100.68M. Pada akhir December 2023, syarikat mempunyai 70.25M saham terbitan. Bilangan saham terbitan biasanya dipengaruhi oleh pecahan saham dan pembelian balik saham.
Sejarah saham terbitan untuk Alumis Inc. (ALMS) dari 2021 hingga 2026
Saham terbitan pada akhir setiap tahun
| Tahun | Saham Terbitan | Ubah |
|---|---|---|
| 2026 (TTM) | 100.68M | 1.39% |
| 2024 | 99.30M | 41.35% |
| 2023 | 70.25M | 243.63% |
| 2022 | 20.44M | 0.00% |
| 2021 | 20.44M | 0.00% |
Saham terbitan bagi syarikat atau pesaing yang serupa
| Syarikat | Saham Terbitan | Perbezaan | Negara |
|---|---|---|---|
| 253.90M | 152.18% |
US
|
|
| 396.00M | 293.32% |
US
|
|
| 478.91M | 375.68% |
AU
|
|
| - | - |
CH
|
|
| 62.19M | -38.23% |
NL
|
